Analysts’ Opinions Are Mixed on These Healthcare Stocks: Boston Scientific (NYSE: BSX), Arcturus Therapeutics (NASDAQ: ARCT) and Oric Pharmaceuticals (NASDAQ: ORIC)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Boston Scientific (BSXResearch Report), Arcturus Therapeutics (ARCTResearch Report) and Oric Pharmaceuticals (ORICResearch Report).

Boston Scientific (BSX)

In a report released today, Marie Thibault from BTIG maintained a Buy rating on Boston Scientific, with a price target of $51.00. The company’s shares closed last Wednesday at $44.31, close to its 52-week high of $46.29.

According to TipRanks.com, Thibault is a 5-star analyst with an average return of 44.9% and a 55.4% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Irhythm Technologies, and Edwards Lifesciences.

Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $59.85, a 37.8% upside from current levels. In a report issued on September 21, Morgan Stanley also reiterated a Buy rating on the stock with a $53.00 price target.

See today’s analyst top recommended stocks >>

Arcturus Therapeutics (ARCT)

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Arcturus Therapeutics today and set a price target of $50.00. The company’s shares closed last Wednesday at $52.58.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 19.6% and a 41.9% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.

Arcturus Therapeutics has an analyst consensus of Hold, with a price target consensus of $64.86.

Oric Pharmaceuticals (ORIC)

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Oric Pharmaceuticals today and set a price target of $53.00. The company’s shares closed last Wednesday at $24.03.

According to TipRanks.com, Burns is a 3-star analyst with an average return of 2.9% and a 36.4% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Black Diamond Therapeutics.

Currently, the analyst consensus on Oric Pharmaceuticals is a Strong Buy with an average price target of $42.75, implying a 78.3% upside from current levels. In a report issued on September 20, Robert W. Baird also maintained a Buy rating on the stock with a $47.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.